You just read:

Despite Increasing Cost Sensitivity of EU5 Payers, Sofosbuvir and Simeprevir are Poised to Reshape the Hepatitis C Virus Market by End of 2015

News provided by

Decision Resources

Dec 09, 2013, 08:00 ET